ECTRIMS: Roche's Ocrevus combats biomarker that may spur MS progression
admin 10th September 2019 Uncategorised 0Roche, already fast in grabbing multiple sclerosis market share with Ocrevus, has new data showing the drug’s impact on a biomarker may help predict disease progression. Patients with relapsing-remitting or primary progressive forms of MS saw their blood neurofilament light chain levels lowered to a healthy donor range after Ocrevus treatment, Roche said.
More: ECTRIMS: Roche's Ocrevus combats biomarker that may spur MS progression
Source: fierce